ICPT - Intercept failed NASH candidate precipitated Alfasigma acquisition
2023-09-30 16:00:00 ET
More on Intercept Pharma
- Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties
- Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade)
- Canaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"
- Intercept Pharma unlikely to see rival offers, other roadblocks, analysts say
For further details see:
Intercept failed NASH candidate precipitated Alfasigma acquisition